AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

REUTERS: AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone.

Lynparza added to bevacizumab reduced the risk of disease progression or death by 41per cent in the overall trial population.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)

Source: Reuters

Bookmark